GlassScriptPhysician profile
Sandra S Osswald
NPI 1407802549
$3,200.75
in general payments reported to CMS, 2019-2025
15 companies · $689 in 2025
The $689 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $218 · 2021: $269 · 2022: $450 · 2023: $478 · 2024: $680 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.65 |
| Education | $104.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $753.47 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $501.65 | 2019-2024 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $380.59 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $244.25 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Pfizer INC. | $236.51 | 2023-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $210.36 | 2020-2023 | Arazlo |
| Galderma Laboratories, L.P. | $153.36 | 2020-2024 | |
| Therakos LLC | $127.19 | 2025 | Cellex, Uvadex |
| Ucb, INC. | $125.00 | 2024 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $124.99 | 2019 | |
| Verrica Pharmaceuticals INC. | $113.32 | 2023 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $112.54 | 2023 | Sotyktu |
| Kyowa Kirin, INC. | $101.00 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $11.75 | 2022 | |
| Organon LLC | $4.77 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Osswald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.